Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease

The 2-deoxy-d-[<sup>18</sup>F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [<...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Matthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, Martin G. Pomper, Steven P. Rowe, Marc Schmalzing, Hans-Peter Tony, Michael Gernert, Patrick-Pascal Strunz, Jan Portegys, Eva-Christina Schwaneck, Ottar Gadeholt, Alexander Weich, Andreas K. Buck, Thorsten A. Bley, Konstanze V. Guggenberger, Rudolf A. Werner
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
GCA
Acceso en línea:https://doaj.org/article/b1962eacd28e46de946478204ed6988a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The 2-deoxy-d-[<sup>18</sup>F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [<sup>18</sup>F]FDG PET/CT on change in initially suspected diagnosis in patients at the time of the scan. Thirty-four patients, who had undergone [<sup>18</sup>F]FDG PET/CT, were enrolled and the initially suspected diagnosis prior to [<sup>18</sup>F]FDG PET/CT was compared to the final diagnosis. In addition, a semi-quantitative analysis including vessel wall-to-liver (VLR) and joint-to-liver (JLR) ratios was also conducted. Prior to [<sup>18</sup>F]FDG PET/CT, 22/34 (64.7%) of patients did not have an established diagnosis, whereas in 7/34 (20.6%), polymyalgia rheumatica (PMR) was suspected, and in 5/34 (14.7%), giant cell arteritis (GCA) was suspected by the referring rheumatologists. After [<sup>18</sup>F]FDG PET/CT, the diagnosis was GCA in 19/34 (55.9%), combined GCA and PMR (GCA + PMR) in 9/34 (26.5%) and PMR in the remaining 6/34 (17.6%). As such, [<sup>18</sup>F]FDG PET/CT altered suspected diagnosis in 28/34 (82.4%), including in all unclear cases. VLR of patients whose final diagnosis was GCA tended to be significantly higher when compared to VLR in PMR (GCA, 1.01 ± 0.08 (95%CI, 0.95–1.1) vs. PMR, 0.92 ± 0.1 (95%CI, 0.85–0.99), <i>p</i> = 0.07), but not when compared to PMR + GCA (1.04 ± 0.14 (95%CI, 0.95–1.13), <i>p</i> = 1). JLR of individuals finally diagnosed with PMR (0.94 ± 0.16, (95%CI, 0.83–1.06)), however, was significantly increased relative to JLR in GCA (0.58 ± 0.04 (95%CI, 0.55–0.61)) and GCA + PMR (0.64 ± 0.09 (95%CI, 0.57–0.71); <i>p</i> < 0.0001, respectively). In individuals with a suspected diagnosis of rheumatic disease, an inflammatory-directed [<sup>18</sup>F]FDG PET/CT can alter diagnosis in the majority of the cases, particularly in subjects who were referred because of diagnostic uncertainty. Semi-quantitative assessment may be helpful in establishing a final diagnosis of PMR, supporting the notion that a quantitative whole-body read-out may be useful in unclear cases.